On March 9, 2026 Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, reported a strategic expansion of its partnership with The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients. Through this partnership, Medidata AI Study Build technology will power Stemline’s oncology portfolio to initiate clinical trials faster to meet the urgent needs of people living with cancer. The announcement follows the milestone of Stemline launching its first oncology study entirely in-house, using the Medidata Data Experience.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
AI for Impact
By transitioning to unified, AI-driven workflows, Stemline is further modernizing the trial lifecycle from protocol to patient. AI Study Build allows Stemline to leverage a vast clinical data set of more than 38,000 trials to automate configurations — reducing the time between protocol finalization and trial startup from months to weeks with:
Rapid study startups: Accelerating the study builds at an unprecedented pace
Internal agility: Empowering Stemline to build and launch future oncology studies independently, powered by the Medidata Data Experience
Stronger oncology research at speed: Delivering high-quality data faster to meet the urgent requirements of research into different cancers
"Stemline is deepening its commitment to advancing oncology research by embracing our established AI foundation and latest AI Study Build capabilities," said Wayne Walker, senior vice president, Data Experience, Medidata. "Stemline’s commitment to adopting Medidata AI-powered technologies sets a high bar for how sponsors can independently harness a unified platform to accelerate the delivery of new therapies for patients. Together, we are setting a new standard for how oncology trials are built and executed."
"Innovation is at the core of our mission to bring transformational treatments to patients, and we recognize the impact of Medidata AI to further streamline our workflows," said Elcin Barker Ergun, CEO of the Menarini Group. "Our expanded partnership with Medidata supports our internal expertise, enabling us to advance crucial research and reflecting the urgency of our team in bringing new options to patients as quickly and safely as possible."
A Foundation of Trusted Collaboration
This expansion builds upon a 14-year relationship between the Menarini Group and Medidata. While the Menarini Group has long utilized the Medidata platform — including Medidata Rave EDC and Medidata eCOA — to manage the end-to-end cycle of its clinical studies, the move to Medidata AI Study Build marks a significant transition. By combining the Menarini Group’s clinical expertise with Medidata’s established AI and Data Experience leadership, Stemline is positioned to advance its oncology portfolio with unprecedented speed and independence.
(Press release, Medidata, MAR 9, 2026, View Source [SID1234663389])